Elo Mutual Pension Insurance Co Buys 30,279 Shares of Exelixis, Inc. $EXEL

Elo Mutual Pension Insurance Co increased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 124.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 54,643 shares of the biotechnology company’s stock after acquiring an additional 30,279 shares during the period. Elo Mutual Pension Insurance Co’s holdings in Exelixis were worth $2,257,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Police & Firemen s Retirement System of New Jersey raised its stake in shares of Exelixis by 0.3% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 102,581 shares of the biotechnology company’s stock worth $4,521,000 after purchasing an additional 274 shares in the last quarter. Richardson Financial Services Inc. increased its holdings in Exelixis by 95.1% during the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock worth $25,000 after buying an additional 292 shares during the last quarter. Evergreen Capital Management LLC increased its holdings in Exelixis by 6.4% during the third quarter. Evergreen Capital Management LLC now owns 5,450 shares of the biotechnology company’s stock worth $225,000 after buying an additional 329 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Exelixis by 5.1% during the third quarter. EverSource Wealth Advisors LLC now owns 7,919 shares of the biotechnology company’s stock worth $327,000 after acquiring an additional 384 shares in the last quarter. Finally, North Star Asset Management Inc. lifted its stake in Exelixis by 0.7% in the third quarter. North Star Asset Management Inc. now owns 57,550 shares of the biotechnology company’s stock valued at $2,377,000 after acquiring an additional 400 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on EXEL shares. TD Cowen reaffirmed a “buy” rating on shares of Exelixis in a report on Wednesday, November 5th. Oppenheimer restated a “market perform” rating and issued a $36.00 price objective on shares of Exelixis in a research note on Wednesday, November 5th. Stifel Nicolaus lifted their target price on Exelixis from $43.00 to $44.00 and gave the stock a “hold” rating in a research note on Wednesday, February 11th. Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a report on Thursday, January 22nd. Finally, Zacks Research raised Exelixis from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $46.94.

Exelixis Stock Performance

EXEL opened at $41.69 on Thursday. The stock has a fifty day moving average of $43.77 and a 200-day moving average of $41.52. The company has a market capitalization of $10.83 billion, a P/E ratio of 15.05, a P/E/G ratio of 0.92 and a beta of 0.41. Exelixis, Inc. has a fifty-two week low of $32.38 and a fifty-two week high of $49.62.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.74 by $0.20. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. The business had revenue of $598.66 million for the quarter, compared to the consensus estimate of $609.17 million. During the same period in the prior year, the company posted $0.55 earnings per share. Exelixis’s revenue was up 5.6% compared to the same quarter last year. On average, equities research analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Insider Activity at Exelixis

In other news, Director Bob Oliver sold 30,250 shares of Exelixis stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $43.81, for a total value of $1,325,252.50. Following the completion of the sale, the director directly owned 21,120 shares in the company, valued at approximately $925,267.20. The trade was a 58.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jack L. Wyszomierski sold 99,574 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total value of $4,382,251.74. Following the transaction, the director owned 279,942 shares in the company, valued at approximately $12,320,247.42. This trade represents a 26.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 362,849 shares of company stock valued at $15,917,463. 2.82% of the stock is currently owned by company insiders.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.